These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1806612)

  • 21. Bromocriptine treatment over 12 years in acromegaly: effect on growth hormone and prolactin secretion.
    Rau H; Althoff PH; Schmidt K; Usadel KH
    Acta Endocrinol (Copenh); 1992 Mar; 126(3):247-52. PubMed ID: 1574954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of long term bromocriptine treatment on glucose intolerance in acromegaly.
    Chiba T; Chihara K; Minamitani N; Goto B; Kadowaki S; Taminato T; Matsukura S; Fujita T
    Horm Metab Res; 1982 Feb; 14(2):57-61. PubMed ID: 7040191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly.
    Colao A; Pivonello R; Auriemma RS; Galdiero M; Savastano S; Lombardi G
    Eur J Endocrinol; 2007 Nov; 157(5):579-87. PubMed ID: 17984237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapeutical effects of bromocriptine (CB 154) in 10 acromegalic subjects. Study of somatotrophic function and clinical survey (author's transl)].
    Fossati P; Asfour M; Brion-Brevan B; Fourlinnie JC; Cappoen JP; Dalle-Furnari MA; Blacker C
    Ann Endocrinol (Paris); 1977; 38(4):291-301. PubMed ID: 332054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Parenteral, depot and repeatable forms of Parlodel LAR bromocriptine in the treatment of hyperprolactinemia syndrome. Comparison with oral Parlodel].
    Dolecek R; Lancranjanová I; Putz Z; Vavros D; Závada M
    Cas Lek Cesk; 1993 Feb; 132(3):81-5. PubMed ID: 8458069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study.
    Ronchi CL; Boschetti M; Degli Uberti EC; Mariotti S; Grottoli S; Loli P; Lombardi G; Tamburrano G; Arvigo M; Angeletti G; Boscani PF; Beck-Peccoz P; Arosio M;
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):512-9. PubMed ID: 17555511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
    Lamberts SW; Zweens M; Verschoor L; del Pozo E
    J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
    Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
    J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of acromegaly with bromocriptine.
    Wang C; Chan V; Yeung RT
    Aust N Z J Med; 1979 Jun; 9(3):225-32. PubMed ID: 288387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects.
    Halse J; Harris AG; Kvistborg A; Kjartansson O; Hanssen E; Smiseth O; Djøsland O; Hass G; Jervell J
    J Clin Endocrinol Metab; 1990 May; 70(5):1254-61. PubMed ID: 2186055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly.
    Ayuk J; Stewart SE; Stewart PM; Sheppard MC
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4142-6. PubMed ID: 12213862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The combination therapy with bromocriptine and cyproheptadine in patients with acromegaly.
    Hanew K; Sugawara A; Shimizu Y; Sato S; Sasaki A; Tazawa S; Ishii K; Saitoh T; Saso S; Yoshinaga K
    Endocrinol Jpn; 1989 Jun; 36(3):429-38. PubMed ID: 2510991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in plasma GH levels and clinical activity during bromocriptine therapy in acromegaly. The value of predictive tests.
    Nortier JW; Croughs RJ; Donker GH; Thijssen JH; Schwarz F
    Acta Endocrinol (Copenh); 1984 Jun; 106(2):175-83. PubMed ID: 6145276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bromocriptine treatment in acromegaly: clinical and biochemical effects.
    Halse J; Haugen HN; Bohmer T
    Acta Endocrinol (Copenh); 1977 Nov; 86(3):464-72. PubMed ID: 335755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bomocriptine treatment of patients with acromegaly resistant to conventional therapy.
    Pelkonen R; Ylikahri R; Karonen SL
    Clin Endocrinol (Oxf); 1980 Mar; 12(3):219-24. PubMed ID: 6993053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS; Musolino NR; Salgado LR; Bronstein MD
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
    Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.